(CercleFinance.com) – AstraZeneca reported on Friday positive preliminary results from a phase III clinical study in the treatment of stomach and gastric junction cancers.
According to these data, its Imfinzi immunotherapy combined with chemotherapy demonstrated a ‘statistically significant and clinically relevant’ improvement in pathological complete response (pCR) rate compared to chemotherapy alone.
In the Imfinzi arm, this rate reached 19% compared to 7% in the control group.
AstraZeneca specifies that the trial involved patients with gastric and esophagogastric junction cancers at early or advanced stages (stage II, III and IVA).
These results are to be presented today at the European Society of Medical Oncology (ESMO) Congress, which opens today in Madrid.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
